RSV F protein vaccine (Novavax)

N/A

Report date: 2024/07/03 21:31:43

Base Information

Drug NameRSV F protein vaccine (Novavax)
Drug Alias NameRSV VLP vaccineRSV F VaccineRSV F-protein nanoparticle vaccineRSV-FSoluble respiratory syncytial virus fusion protein vaccine +[9] 
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPhilippinesNew Zealand +[11] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovavax
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovavax
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A